文献速递重症综合管理与镇静镇痛

低低密度脂蛋白水平与脓毒症死亡率增加相关,但无因果贡献

Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论脓毒症患者低LDL水平与28天死亡率增加相关,但孟德尔随机化分析提示低LDL本身不因果性导致不良结局。

该研究采用孟德尔随机化策略回顾性分析两个脓毒症患者队列。第一队列为急诊科观察性研究纳入的200例脓毒症患者,复现了低LDL水平与28天死亡率增加相关的发现。第二队列为血管加压素与脓毒性休克试验中632例基因分型患者,计算与LDL水平相关的PCSK9和HMGCR遗传评分。HMGCR遗传评分与死亡率增加无关,PCSK9遗传评分反而与死亡率降低相关。作者认为低LDL水平本身不因果性导致不良脓毒症结局,PCSK9遗传评分结果提示增加LDL清除可能改善脓毒症结局。

要点

  • 第一队列200例急诊脓毒症患者中,复现低LDL水平与28天死亡率增加相关。
  • 血管加压素与脓毒性休克试验632例基因分型患者中,HMGCR遗传评分与死亡率增加无关。
  • PCSK9遗传评分与死亡率降低相关,而非增加,与因果假设方向相反。
  • 作者认为低LDL水平本身不因果性导致不良脓毒症结局。
  • PCSK9遗传评分结果提示增加LDL清除可能改善脓毒症结局。

适用人群与场景

  • 第一队列:某医院急诊科观察性研究纳入的200例脓毒症患者。
  • 第二队列:血管加压素与脓毒性休克试验中632例基因分型患者。
  • 场景:三级教学医院临床研究队列中的脓毒症患者。

研究设计与关键结果

  • 研究类型:两个脓毒症患者队列的回顾性分析,采用孟德尔随机化策略。
  • 第一队列200例急诊脓毒症患者中,复现低LDL水平与28天死亡率增加相关。
  • 第二队列632例血管加压素与脓毒性休克试验基因分型患者中,计算HMGCR和PCSK9单核苷酸多态性遗传评分。
  • HMGCR遗传评分(已知与低LDL水平直接相关)与死亡率增加无关。
  • PCSK9遗传评分(已知与低LDL水平直接相关)与死亡率降低相关,而非增加。

证据类型、等级与局限

  • 证据类型:回顾性分析两个脓毒症患者队列的孟德尔随机化研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为低LDL水平本身不因果性导致不良脓毒症结局。
  • 作者认为PCSK9遗传评分结果提示增加LDL清除可能改善脓毒症结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Low low-density lipoprotein levels are associated with increased mortality in sepsis. Whether low low-density lipoprotein levels contribute causally to adverse sepsis outcome is unknown.

DESIGN: Retrospective analysis of two sepsis patient cohorts using a Mendelian Randomization strategy.

SETTING: Sepsis patients enrolled into clinical research cohorts at tertiary care teaching hospitals.

PATIENTS: The first cohort included 200 sepsis patients enrolled in an observational study in a hospital Emergency Department. The second cohort included genotyped patients enrolled in the Vasopressin and Septic Shock Trial.

INTERVENTIONS: Retrospective analysis of these patient datasets. In 632 patients enrolled in Vasopressin and Septic Shock Trial, Proprotein Convertase Subtilisin/Kexin type 9, and 3-Hydroxy-3-Methylglutaryl-CoA Reductase single nucleotide polymorphisms known to be associated with low-density lipoprotein levels were genotyped, and a genetic score related to low-density lipoprotein levels was calculated.

MEASUREMENTS AND MAIN RESULTS: In the first cohort, we replicated the finding that low low-density lipoprotein levels are associated with increased 28-day mortality. In genotyped patients in the Vasopressin and Septic Shock Trial trial, we found that the 3-Hydroxy-3-Methylglutaryl-CoA Reductase genetic score, known to be directly related to low low-density lipoprotein levels, was not associated with increased mortality. Surprisingly the Proprotein Convertase Subtilisin/Kexin type 9 genetic score, known to be directly related to low low-density lipoprotein levels, was associated with decreased (not increased) mortality.

CONCLUSIONS: Both 3-Hydroxy-3-Methylglutaryl-CoA Reductase and Proprotein Convertase Subtilisin/Kexin type 9 genetic scores should have been associated with increased mortality if low low-density lipoprotein levels contributed causally to sepsis mortality. But this was not the case, and the opposite was observed for the Proprotein Convertase Subtilisin/Kexin type 9 genetic score. This suggests that low-density lipoprotein levels, per se, do not contribute causally to adverse sepsis outcomes. The Proprotein Convertase Subtilisin/Kexin type 9 genetic score finding raises the possibility that increased low-density lipoprotein clearance (the effect of these Proprotein Convertase Subtilisin/Kexin type 9 genotypes) may contribute to improved sepsis outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Walley KR, Boyd JH, Kong HJ, et al. Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis. Crit Care Med. 2019. PMID: 30394916. doi:10.1097/CCM.0000000000003551

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。